linjc16/ctgov huggingface dataset:
Long Term Follow up of Chronic HCV Patients Receiving DAAS

Study Overview
=================
Brief Summary
-----------------
Follow up of Chronic hepatitis C Patients with moderate to severe fibrosis and cirrhosis treated with Direct Acting Antivirals after Sustained Virological Response for 4-5 years to detect changes in hepatic fibrosis and liver functions.

Detailed Description
-----------------
Treatment of chronic hepatitis C is evolving rapidly. Three classes of direct-acting antiviral agents, including inhibitors of the HCV NS3/4A protease, NS5B polymerase, and NS5A have been approved for the treatment of patients with chronic hepatitis C, both in combination with pegylated Interferon (Peg-IFN) / ribavirin (RBV) and, recently, in interferon-free combination. The objective of chronic hepatitis C treatment is to achieve SVR which is defined as the absence of viral replication at 12 or 24 weeks after treatment completion. SVR reduces morbidity and mortality and is equivalent in most cases to cure the HCV infection. Studies have demonstrated that SVR is associated with histological improvement, assessed by liver biopsy, and with the prevention of complications, such as the development of liver cirrhosis and HCC.

Official Title
-----------------
Long Term Follow up of Chronic Hepatitis C Patients Treated With Direct Acting Antivirals After Sustained Virological Response

Conditions
-----------------
Chronic Hepatitis c

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic HCV patients with moderate to severe hepatic fibrosis (F2: F4) or cirrhosis who received direct-acting antivirals and achieved SVR. Exclusion Criteria: Other liver diseases as Chronic hepatitis B and autoimmune liver disease. HIV co-infection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in hepatic fibrosis | Shear wave elastography | 4 years after end of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in serum albumin level | change in liver function | 4 years after end of treatment | 
| change in prothrombin level | change in liver function | 4 years after end of treatment | 
| change in bilirubin level | change in liver function | 4 years after end of treatment |
Triage of Abdominal Pain in the Emergency Department

Study Overview
=================
Brief Summary
-----------------
The investigators aim to evaluate in a retrospective study the performance of the Swiss Emergency Triage Scale to identify at the door of the Emergency Department patients requiring emergent intervention.

Detailed Description
-----------------
All patients are triaged at the door of our Emergency Department using the Swiss Emergency Triage Scale. Patients with abdominal pain may be triaged in two different emergency levels (level 2: medical evaluation within 20 minutes, level 3: medical evaluation within 2 hours). These levels are determined using a set of specific criteria. The aim of this study is to evaluate the validity of these specific criteria in order to identify promptly patients with abdominal pain the will require an emergent intervention during their stay in the Emergency Department.

Official Title
-----------------
Evaluation of Triage Criteria for Abdominal Pain in the Emergency Department

Conditions
-----------------
Abdominal Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >= 16 y abdominal pain as the main complaint Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with abdominal pain<br>Adult patients admitted to the Emergency Department with a main complaint of abdominal pain | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Emergency intervention | Emergency intervention is a composite outcome of: emergency surgical intervention or radiological intervention or emergent endoscopy | participants will be followed for the duration of hospital stay, an expected average of 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to medical evaluation | We will evaluate the delay between triage evaluation and medical evaluation. We will compute the percentage of patients evaluated within timeframe accordingly to the Swiss Triage Emergency Scale | participants will be followed for the duration of emergency department stay, an expected average of 5 hours |
Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia

Study Overview
=================
Brief Summary
-----------------
To monitor the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.

Detailed Description
-----------------
The primary aim of this research is to identify the most robust site for monitoring hypovolemia as well as assess changes in peripheral waveforms monitored by the pulse oximeter collected from different sites (finger, ear, forehead, and nose), blood pressure, cerebral oximetry and peripheral venous pressure during gradual hypovolemia induced by lower body negative pressure (LBNP) in healthy volunteers.

Official Title
-----------------
Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia

Conditions
-----------------
Hypovolemia, Hemodynamic Instability

Intervention / Treatment
-----------------
* Diagnostic Test: Lower body negative pressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: * Healthy volunteers aged 20-45 with Exclusion Criteria: Pregnant women Under 20 years of age Subjects with coronary artery disease, diabetes, epilepsy and hypertension

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Lower body negative pressure|We will be monitoring the changes in central and peripheral monitors/waveforms during gradual hypovolemia induced by lower body negative pressure in healthy volunteers.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify the most robust site for monitoring hypovolemia utilizing pulse oximeter waveforms. | Data will be summarized using mean (SD) for normally distributed data, median (interquartile range) for non-normal data. linear regression method will be used to model the changes of our dependent variable from baseline during blood loss. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examine the relationship between central hemodynamic changes (cardiac output) with changes in respiratory variability of PPG waveforms collected from different sites during hypovolemia and fluid resuscitation | Data will be summarized using mean (SD) for normally distributed data, median (interquartile range) for non-normal data. linear regression method will be used to model the changes of our dependent variable from baseline during blood loss. | 2 years |
Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study

Study Overview
=================
Brief Summary
-----------------
Failure of Weaning from ECMO is a serious complication, reaching an incidence between 29 and 58%. Inotrops are frequently used to help separating patient from ECMO. Levosimendan is an ino-dilatatory medication and was used in different clinical settings. The aim of this study was to evaluate the benefit with levosimendan when used in weaning process.

Official Title
-----------------
Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study

Conditions
-----------------
Cardiogenic Shock

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 Patient requiring the need for short-term assistance Patient who has agreed to use his medical data for research purposes Exclusion Criteria: Refusal to participate in the study Non-weaning attempts due to a death under assistance or a relay by a long-term assistance or heart transplant Non-cardiac indications of assistance (indication of pulmonary replacement) Subject under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of the incidence of weaning failure between patients with levosimendan and others |  | Data were recorded from admission until 48 hours after weaning from ECMO | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Levosimendan, Veno-arterial ECMO, Weaning
Drainage is Not Necessary Procedure After Laparoscopic Cholecystectomy Due to Severe Acute Cholecystitis

Study Overview
=================
Brief Summary
-----------------
Laparoscopic cholecystectomy (LC) is the current preferred method of cholecystectomy. The role of routine drainage after LC to decrease postoperative morbidity is still an issue of considerable debate. The goal of this study was to assess to role of drains in LC, performed for acute inflamed gallbladder.

Conditions
-----------------
Acute Cholecystitis, Empyema

Intervention / Treatment
-----------------
* Procedure: Surgical drainage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acute cholecystis Laparoscopic cholecystectomy KAROFSKY PERFORMANCE SCALE > 70 No history of major operation Exclusion Criteria: NYHA class > 3 Open cholecystectomy No- compliance Intraoperative injuries Inadequate hemostasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1 arm<br>Patients under LC. Allocated to drain placement . Drainage was removed if the drainage amount was less than 20cc. | Procedure: Surgical drainage<br>* Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.<br>|
| Active Comparator: 2 arm<br>Patients under LC. Allocation to sham drain, | Procedure: Surgical drainage<br>* Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of postoperative complication occurrence |  | whinin 1 week and 8 weeks postoperatively |
Comparison of Different Anterior Cruciate Ligament Surgery Techniques in Skeletally Immature Patients.

Study Overview
=================
Brief Summary
-----------------
This cohort study compares to groups of patients with reconstruction of anterior cruciate ligament (ACL). Patients in group 1 had ACL-reconstruction in the years 2001-2010 with a transphyseal drilling technique. Patient in group 2 had ACL-reconstruction in the years 2013-2018 with a physeal sparing technique. Data including: x-ray exam, patient reported questionnaires and clinical evaluation will be compared between the 2 groups.

Official Title
-----------------
Comparison of Different Anterior Cruciate Ligament Surgery Techniques in Skeletally Immature Patients.

Conditions
-----------------
Anterior Cruciate Ligament Rupture

Intervention / Treatment
-----------------
* Procedure: ACL-reconstruction


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ACL reconstruction as skeletally immature Exclusion Criteria: Other ligament injuries in index knee Other ligament injuries in opposite knee Revision ACL reconstruction Pregnant Not able to read or understand the danish languages

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transphyseal drilling technique<br> | Procedure: ACL-reconstruction<br>* Surgery technique in skeletally immature patients<br>|
| Physeal sparing drilling technique<br> | Procedure: ACL-reconstruction<br>* Surgery technique in skeletally immature patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leg-length differences | X-ray evaluation | 2 Years Follow-up | 
| Knee Angle differences | X-ray evaluation | 2 Years Follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knee Laxity | Clinical evaluation with rolimeter (arthrometer) | 2 Years Follow-up | 
| IKDC-Questionnaire | The International Knee Documentation Committee (IKDC Questionnaire) | 2 Years Follow-up | 
| Tegner-Questionnaire | Tegner (Activity function score) | 2 Years Follow-up | 
| KOOS- Questionnaire | Knee injury and Osteoarthritis Outcome Score (KOOS) | 2 Years Follow-up |
Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE

Study Overview
=================
Brief Summary
-----------------
The HOKUSAI post VTE study contains of two different research questions; one on the long term outcomes of deep vein thrombosis and one on the long term effects of pulmonary embolism, post thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH) respectively. Our aim of the study is to compare the long term outcomes along with the quality of life assessment of VTE in a group treated with heparin+VKA versus a group treated with heparin+edoxaban in the acute setting.

Official Title
-----------------
Long-term Outcome After Edoxaban Versus Vitamin K Antagonists for Acute VTE

Conditions
-----------------
Venous Thromboembolic Disease, Post Thrombotic Syndrome, Chronic Thromboembolic Pulmonary Hypertension, Quality of Life

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant in the HOKUSAI VTE trial Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients treated with heparin+edoxaban for VTE<br>Patients treated with heparin+edoxaban for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised. | Other: Observation<br>* No intervention<br>|
| Patients treated with heparin+VKA for VTE<br>Patients treated with heparin+VKA for a venous thromboembolic event during the HOKUSAI trial, for which they were randomised. | Other: Observation<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post thrombotic syndrome (PTS) | PTS according to Villalta | up to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chronic thromboembolic pulmonary hypertension (CTEPH) | according to clinical and objective criteria | up to 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post thrombotic syndrome, Edoxaban, Vitamin K antagonist, Chronic Thromboembolic Pulmonary Hypertension, Quality of Life
Evaluation of a Rapid Microscopic Diagnostic System for Different Vaginitis Conditions

Study Overview
=================
Brief Summary
-----------------
Evaluate the diagnostic performance of the Gyni™ device to detect different vaginitis conditions by comparison to microscopic diagnosis and related lab tests.

Detailed Description
-----------------
During gynecological exams, vaginal discharge samples will be are taken for testing the pH level, microscopic examination and laboratory examinations (vaginal cultures and sexually transmitted infections). One additional sample will be taken intended for the Gyni™ system diagnosis. This additional examination will be performed in the clinic by pulling the cytobrush through a dedicated cartridge and scanning it in the Gyni table-top scanner. The result diagnosis will be anonymously kept in the cloud. The diagnosis suggested by the Gyni system will not be visible to the physician in order to prevent any bias. Results from the physician, from the device and from the lab will be summarized and compared by the chief investigator

Official Title
-----------------
Evaluation of a Rapid Microscopic Diagnostic System for Different Vaginitis Conditions

Conditions
-----------------
Bacterial Vaginosis, Candida Albicans Vulvovaginitis, Candida Vulvovaginitis, Trichomonas Vaginitis, Atrophic Vaginitis, Desquamative Inflammatory Vaginitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women with vaginal complaints: Discharge, Malodor, Itching, Irritation, Dyspareunia, Pain Age >= 18y Exclusion Criteria: Age < 18y Not eligible to sign an informed consent Vaginal discharge samples found microscopically not interpret-able by the investigator due to patient using vaginal creams, ointments, lubricants or sperm presence. During menstruation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Symptomatic vaginitis patients<br>Symptomatic patients evaluated in the clinic for vulvovaginal symptoms. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic performance | Specificity and sensitivity of the device performance in regard to vaginitis conditions | 12 months |
Bupropion as a Smoking Cessation Aid in Alcoholics

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the use of time-released bupropion (Wellbutrin) in patients receiving treatment for alcohol abuse/dependence as an aid to stop smoking. Patients will receive either a time-released bupropion or placebo. Both groups will receive nicotine replacement therapy during the 9 week study. A final followup assessment will be conducted 6 months from the start of treatment.

Official Title
-----------------
Bupropion as a Smoking Cessation Aid in Alcoholics

Conditions
-----------------
Alcoholism, Smoking

Intervention / Treatment
-----------------
* Drug: bupropion (Wellbutrin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Currently a patient in the Omaha VA Medical Center, Substance Abuse Treatment Center (SATC) or at Catholic Charities Campus for Hope. Have a diagnosis of alcohol abuse or alcohol dependence. Smoke 20 or more cigarettes/day (may also smoke pipes/cigars). Be interested in quitting smoking. Provide name, addresses, and phone numbers of at least two individuals who can provide information on their alcohol, nicotine, and other drug use during the follow-up period. If female, patient must a) be of non-childbearing potential, b) have a negative pregnancy test, c) sign a document stating they do not plan on becoming pregnant during the study. Agree to sign informed consent. Able to read and understand study-related forms and procedures. Exclusion Criteria: Advanced cardiac, pulmonary, renal, or liver disease. History of seizures. History of brain tumor or significant head trauma. History of bulimia or anorexia nervosa. Current major depressive disorder or past history of panic disorders, schizophrenia, or bipolar affective disorder. Using psychoactive drugs. Receiving treatment with medications that lower seizure thresholds. Use of an investigational drug in any study in the past four weeks. Currently using any asthma medication. Used time-released bupropion in the past 12 months. Currently using any other treatments to stop smoking.

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: bupropion (Wellbutrin)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |